Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.43 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | MGMT | P16455 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522454 | 0.85 | PARP10 (0.50) | MAPK14 | |
| SCHEMBL3522703 | 0.84 | NR4A1 (0.48) | MAPK14HPGDMEN1KMT2A | |
| SCHEMBL3522032 | 0.83 | MAOB (0.48) | MAOBMAPK14 | |
| SCHEMBL3522176 | 0.83 | MAPK14 (0.53) | MAOBMAPK14HPGDMEN1KMT2A | |
| SCHEMBL3520099 | 0.81 | HDAC6 (0.45) | KCNH2 | |
| SCHEMBL3521536 | 0.81 | MAPT (0.39) | MAPK14RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL3524455 | 0.81 | FGFR1 (0.50) | HPGDMEN1KMT2APKMCA1 | |
| SCHEMBL3526023 | 0.80 | MAPT (0.42) | MAPK14L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4383498 | 0.79 | MAPK14 (0.57) | MAOBMAPK14KCNH2MCHR1LOXL2 | |
| SCHEMBL3524427 | 0.79 | MAPK14 (0.48) | MAOBMAPK14MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1753731-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | Pharmacia Corporation (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004087677-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAOB 1718/4885MAPK14 38/4885HCAR1 1278/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAOB 1814/4885MAPK14 29/4885HCAR1 2112/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAOB 1718/4885MAPK14 38/4885HCAR1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.